financetom
Business
financetom
/
Business
/
BRIEF-Summit Grove Partners Reports 9.5% Passive Stake In Great Elm Capital Corp
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Summit Grove Partners Reports 9.5% Passive Stake In Great Elm Capital Corp
Dec 12, 2024 6:16 AM

Dec 12 (Reuters) - SUMMIT GROVE PARTNERS LLC:

* SUMMIT GROVE PARTNERS, LLC REPORTS 9.5% PASSIVE STAKE IN

GREAT

ELM CAPITAL CORP AS OF DEC 11 - SEC FILING

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Activist Bluebell proposes Google executive as Telecom Italia CEO
Activist Bluebell proposes Google executive as Telecom Italia CEO
Apr 11, 2024
MILAN, April 11 (Reuters) - Activist investor Bluebell Capital Partners is proposing to nominate an outgoing Google executive as candidate for the role of CEO of Telecom Italia (TIM), in a challenge to Pietro Labriola's bid for a second term. In a document presenting Bluebell's vision for TIM, seen by Reuters, it proposed Laurence Lafont, the outgoing vice-president for strategic...
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Apr 11, 2024
On Wednesday, Vertex Pharmaceuticals Incorporated ( VRTX ) agreed to acquire Alpine Immune Sciences Inc ( ALPN ) for $65 per share or approximately $4.9 billion in cash.  Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand).  Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA...
Market Chatter: Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
Market Chatter: Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
Apr 11, 2024
09:03 AM EDT, 04/11/2024 (MT Newswires) -- Western pharmaceutical companies Eli Lilly ( LLY ) , Vertex Pharmaceuticals ( VRTX ) and BeiGene ( BGNE ) are seeking alternative suppliers amid the proposed Biosecure Act in the US that would forbid US firms getting federal grant money from working with four Chinese biotech companies, including WuXi AppTec and WuXi Biologics,...
Novartis taps Arvinas' cancer drug for up to $1 billion
Novartis taps Arvinas' cancer drug for up to $1 billion
Apr 11, 2024
April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas ( ARVN ) to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas ( ARVN ) said on Thursday. Shares of Connecticut-based Arvinas ( ARVN ) rose more than 6% to $39 in premarket trade. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved